Indeed, TME subtypes exhibiting fibrosis or a mesenchymal subtype despite high immune infiltrate are unresponsive to pembrolizumab (27), suggesting that therapeutic targeting the Hippo/Yap1 or STAT3 pathways could potentially enhance anti-tumor immune responses. Here, STAT3 is linked to neoplasm.